CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.) コンサ―ト・ファ―マシュ―ティカルズ

 CNCEのチャート


 CNCEの企業情報

symbol CNCE
会社名 Concert Pharmaceuticals Inc (コンサ―ト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンサート・ファーマスーティカル(Concert Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は小分子医薬品の発見と開発に従事する。同社は医薬品の開発を通じて事業を行う。同社の重水素化化学物質プラットフォーム(DCEプラットフォーム)は各種治療領域にある可能性を有する。同社の製品好捕にはAVP-786、CTP-656、CTP-730、CTP-543、JZP-386等を含む。同社の製品候補であるCTP-656は、G551D突然変異を含むゲーティング変異を有する患者にある嚢胞性線維症の治療のために開発中次世代増強剤である。CTP-543はルキソリチニブを改変することでコンサートのジュウテリウム化学技術を応用することにより発見された。AVP-786はデキストロメトルファンと超低用量のキニジンの組み合わせである。CTP-730は各種炎症性疾患の治療の可能性を有するホスホジエステラーゼ4(PDE4)阻害剤である。   コンサ―ト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。臨床段階の低分子薬の開発に従事。主要パイプライン製品候補は、多発性硬化症および脊髄損傷に関連した痙性のためのCTP-354、糖尿病性腎症のためのCTP-499、神経学的および精神障害のためのAVP-786など。   Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
本社所在地 99 Hayden Avenue Suite 500 Lexington MA 02421 USA
代表者氏名 Richard H. Aldrich リチャードH.アルドリッチ
代表者役職名 Independent Chairman of the Board Co-Founder
電話番号 +1 781-860-0045
設立年月日 38808
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 64人
url www.concertpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cnce
adr_tso
EBITDA EBITDA(百万ドル) 101.93900
終値(lastsale) 15.5
時価総額(marketcap) 362932887.5
時価総額 時価総額(百万ドル) 337.17640
売上高 売上高(百万ドル) 154.33700
企業価値(EV) 企業価値(EV)(百万ドル) 147.00540
当期純利益 当期純利益(百万ドル) 103.45900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Concert Pharmaceuticals Inc revenues increased from $35K to $10.5M. Net loss applicable to common stockholders decreased 32% to $17.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General_Admin exp decrease of 14% to $7.8M (expense) Investment Income increase from $292K to $1.3M (income).

 CNCEのテクニカル分析


 CNCEのニュース

   Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2020/01/30 21:01:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announces closing of public offering and full exercise of underwriters’ option to purchase additional shares.
   Concert Pharmaceuticals Announces Pricing of Public Offering  2020/01/28 14:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals Announces Pricing of Public Offering
   Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock  2020/01/27 21:02:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert intends to offer and sell shares of its common stock in an underwritten registered public offering.
   Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata  2020/01/22 13:40:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Concert received a Notice of Allowance from the USPTO for a patent application related to CTP-543 for alopecia areata.
   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.
   Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2020/01/30 21:01:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announces closing of public offering and full exercise of underwriters’ option to purchase additional shares.
   Concert Pharmaceuticals Announces Pricing of Public Offering  2020/01/28 14:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals Announces Pricing of Public Offering
   Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock  2020/01/27 21:02:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert intends to offer and sell shares of its common stock in an underwritten registered public offering.
   Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata  2020/01/22 13:40:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Concert received a Notice of Allowance from the USPTO for a patent application related to CTP-543 for alopecia areata.
   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.
   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.
   Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia  2019/12/02 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiates Phase 2 to evaluate the safety and efficacy of CTP-692 in patients with schizophrenia who are stable on an antipsychotic medication.
   Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update  2019/11/07 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today to discuss third quarter financial results and provide a business update.
   Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia  2019/11/06 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast with Dr. Joseph Coyle on November 14, 2019, focused on CTP-692 and schizophrenia.
   Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for  2019/10/31 14:35:01 Zacks Investment Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンサ―ト・ファ―マシュ―ティカルズ CNCE Concert Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)